Predictors of Response to DMARDs in Rheumatoid Arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial studies rheumatoid arthritis (RA) patients starting or adjusting DMARD medicines and looks for signs that predict who responds best. It may help doctors choose more effective treatment sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of rheumatoid arthritis (RA).
- You are older than 19 years when RA was diagnosed.
- Your RA is active right now (at least one swollen joint), and you meet specific long-term symptom signs.
- You are starting a DMARD medication listed in the study, or your DMARD dose has been stable for at least 6 weeks.
- Your blood tests are within study safety ranges (not too low blood counts or liver/kidney issues).
- You can attend study visits around enrollment and a follow-up at about 8 and 16 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication (BMS-986454) for people with rheumatoid arthritis who haven't responded well enough to methotrexate. It aims to see if the drug is safe and how it works in the body.
This study tests a new medication called AZD1163 for people with rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if the drug can safely reduce joint swelling and pain.
This study follows people with rheumatoid arthritis (RA) who have achieved remission—meaning their disease is well-controlled—to see how safely doctors can reduce or stop their medications over time. You would be monitored regularly to ensure your RA stays in remission.
This trial tests a step-by-step plan for treating rheumatoid arthritis when current medicines aren’t controlling the disease. It compares how well a targeted approach works by adjusting treatment for people who need a TNF inhibitor.
This study tests whether increasing the dose of methotrexate or switching from pills to injections can better control rheumatoid arthritis symptoms. It aims to find the best way to use this common medication to reduce joint pain and swelling.
This study compares two combination treatments for rheumatoid arthritis in people whose current methotrexate or leflunomide isn’t working well enough. It aims to see whether adding a targeted therapy works better than the standard add-on of sulfasalazine plus hydroxychloroquine.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.